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Abstract
Over the last decade there have been significant advances in the discovery and understanding of the cannabinoid system
along with the development of pharmacologic tools that modulate its function. Characterization of the crosstalk between
nicotine addiction and the cannabinoid system may have significant implications on our understanding of the
neurobiological mechanisms underlying nicotine dependence. Two types of cannabinoid receptors (CB1 and CB2) have
been identified. CB1 receptors are expressed in the brain and modulate drug taking and drug seeking for various drugs of
abuse, including nicotine. CB2 receptors have been recently identified in the brain and have been proposed to play a
functional role in mental disorders and drug addiction. Our objective was to explore the role of CB2 receptors on
intravenous nicotine self administration under two schedules of reinforcement (fixed and progressive ratio) and on nicotine
seeking induced by nicotine priming or by nicotine associated cues. For this, we evaluated the effects of various doses of
the selective CB2 antagonist AM630 (1.25 to 5 mg/kg) and CB2 agonist AM1241 (1 to 10 mg/kg) on these behavioral
responses in rats. Different groups of male Long Evans rats were trained to lever press for nicotine at a unit dose of 30 mg/
kg/infusion. Subsequently, animals were randomized using a Latin-square design and injected with either AM1241 or
AM630 using a counterbalanced within subject design. Administration of the CB2 ligands did not affect either nicotine-
taking nicotine-seeking behavior. Our results do not support the involvement of CB2 receptors in nicotine-taking or
nicotine-seeking behavior.
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Introduction
Cigarette smoking is responsible for 5 million deaths worldwide
every year. The mechanisms underlying tobacco smoking are of
wide interest and clearly there is still a need for more effective
medications to help in smoking cessation and prevent relapse [1].
The cannabinoid system appears to play a critical role in
mediating the reinforcing effects of nicotine as well as relapse to
nicotine-seeking behaviour. The cannabinoid system consists of
CB1 and CB2 receptors, the endogenous cannabinoid receptor
ligands, anandamide, and 2-arachidonoylglycerol (2-AG) [2,3], in
addition to the enzymes responsible for their degradation which
are fatty acid amide hydrolase (FAAH) and monoacylglycerol
lipase 2-AG, respectively [2,4].
The CB1 receptor is highly expressed in the CNS, and is
considered the most abundant G protein coupled receptor in the
brain [5]. Cannabinoids act at CB1 receptors located presynap-
tically to elicit changes in the synaptic efficacy of central neuronal
circuits that are involved in several processes including reward [6].
The CB2 receptors are predominantly expressed outside the
central nervous system on immune tissues [7]. Recently, the
expression of CB2 receptors has been reported in the brain. First,
the expression of CB2 receptors was demonstrated in rat
microglial cells and other cells in the brain associated with
inflammation [8–11]. Then, CB2 receptor mRNAs were detected
in rat brain (cerebellum, cortex, and brainstem) using reverse
transcription polymerase chain reaction (RT-PCR) [12]. More-
over, CB2 receptor protein was detected using Western blotting
and immunohistochemistry and evidence that CB2 receptors are
functional and have antiemetic activity was obtained using
intracranial ligand infusion [12]. More recently, it has been
suggested that CB2 receptors may be involved in mental disorders
and drug addiction [13,14]. It has been reported that selective
blockade of CB2 receptors prevented the development of alcohol
preference, while selective activation of CB2 receptors enhanced
alcohol preference, in mice subjected to chronic mild stress [13].
In addition, it has been recently reported that selective activation
of CB2 receptors, reduced the reinforcing effects of cocaine and
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and CB1 receptor knockout mice, but not in CB2 receptor
knockout mice [15]. These findings support the notion that CB2
receptors are involved in modulating the reinforcing effects of
drugs of abuse.
Most of the studies conducted so far, have explored the effects of
activation or inactivation of CB1 receptors on drug-taking and
drug-seeking behavior for various drugs of abuse, including
nicotine. [16–21]. However, to our knowledge, no studies have
examined the role of CB2 receptors on nicotine-taking and
reinstatement of nicotine-seeking behavior. Here, we explored the
impact of selective blockade and/or activation of CB2 receptors
on nicotine self-administration behavior under fixed-ratio and
progressive-ratio schedules of reinforcement and on reinstatement
of nicotine-seeking behavior induced by reintroduction of nicotine-
associated cues and by nicotine priming.
Materials and Methods
Animals
Male Long Evans rats (Charles River, Lachine, PQ, Canada)
experimentally naive at the start of the study and initially weighing
250 to 275 g were used. All rats were individually housed in a
temperature-controlled environment on a 12-h reverse light/dark
cycle (lights off from 07:00 hours to 19:00 hours). Prior to any
experimental manipulation, animals were given a minimum of 7
days to habituate to the colony room, during which they were
weighed, handled and received unlimited access to both food and
water. After habituation, all rats were diet restricted to 5 Pellets or
20 gms daily and had free access to water. Food restriction
continued until all the experiments were completed. All the
experimental procedures described in this report were carried out
in compliance with the guidelines of the Canadian Council on
Animal Care (compatible with NIH guidelines), and were
reviewed and approved by the Centre for Addiction and Mental
Health (CAMH) Animal Care Committee (Protocol no. 543).
Apparatus
Nicotine intravenous self-administration studies were carried
out in commercially available experimental chambers (Med
Associates, St. Albans, Vt., USA) enclosed in sound attenuating
boxes and equipped with two levers, a house light and 2 cue lights,
one located above each lever. For half the animals, the left lever
was the active lever and for the other half the right lever was the
active lever. Session start was signaled by the illumination of the
house-light and presentation of the levers. Pressing on the active
lever resulted in the delivery of nicotine (30 mg/kg/infusion) when
schedule requirements were met, accompanied by dimming of the
house light and illumination of the cue light above the active lever.
This continued for 60 seconds (time out period), during which
further pressing on the active lever was recorded but had no
programmed consequences. Pressing on the inactive lever was
recorded, but had no programmed consequences throughout the
session.
Experimental Procedures
Food-maintained behavior. Techniques for initial
acquisition of food-maintained behavior were similar to those
already reported [22–24]. Animals learned to lever press for food
reinforcement on a continuous reinforcement (CRF) schedule, in
which each press on the active lever resulted in the delivery of a
45 mg food pellet. During the acquisition sessions, the house light
was on and pressing the active lever resulted in the delivery of food
with no illumination of the cue light above the levers. Daily 1-h
acquisition sessions were conducted for 5 days. Once food-
maintained behavior was acquired, intravenous catheters were
surgically implanted.
Intravenous catheterization. Surgical procedures for
implantation of chronic intravenous catheters were similar to
those reported previously [22,24]. Briefly, catheters were
implanted into the jugular vein, exiting between the scapulae.
Surgery was performed under anesthesia induced by xylazine
(10 mg/kg, intraperitoneal (IP) and ketamine hydrochloride
(90 mg/kg, IP). Incision sites were infiltrated with the
subcutaneous (SC) local anesthetic marcaine (0.125%).
Buprenorphine was given for post-operative analgesia (0.03 mg/
kg, SC), and a single dose of penicillin (30,000 units, IM) was
administered at the completion of surgical procedures. Animals
were allowed to recover for a 1-week period before starting drug
self-administration sessions.
Self-administration procedures. Acquisition of nicotine
self-administration behavior was performed under a fixed-ratio
(FR) schedule of reinforcement at a unit dose of 30 mg/kg/infusion
of nicotine base. Session duration was 60 min. The start of each
60 min session was signaled by illumination of the house light. In
the presence of the illuminated house light, completion of the
schedule requirement on the active lever (i.e. 1 to 5 lever presses
under FR1 to FR5) resulted in the delivery of a nicotine infusion.
Each infusion was followed by a time out (TO) period of
60 seconds, during which the house light was dimmed, the cue
light above the active lever illuminated, and lever press responses
had no programmed consequences.
During the first five days of acquisition, response requirements
were FR1 (i.e., each active lever press during the time-in period
resulted in the delivery of a nicotine infusion), then FR2 for three
days, then increased to reach a final value of FR5. Training was
continued until the self-administration behavior was stable and the
animals had a 15–20 day history of nicotine self-administration.
Self-administration sessions were conducted mostly 5 days a week.
Testing under the FR5 schedule of reinforcement. Animals
were considered to have acquired stable nicotine self-administration
when they (1) pressed the active lever more than twice the number of
times they pressed the inactive lever, (2) received a minimum of 10
infusions per 1-h session and (3) had less than 20% variation in the
number of infusions earned per session over 2 consecutive sessions.
Once stability was reached, the animals were given I.P. injections of
vehicle 30 minutes before the start of the session, to habituate them to
the injection procedure for an additional three days. Rats were
randomized using a Latin-square design and were then tested with
vehicle (0 mg/kg) and different doses of AM630 or AM1241 in a
counter-balanced, within-subject design. Drugs were administered
intraperitoneally 30 min before the session. Two separate groups of
animals were used, one for testing the effects of the CB2 agonist
AM1241 (N=10) and the other for testing the CB2 antagonist
AM630 (N=12) on nicotine self-administration behavior under the
fixed-ratio schedule, with drugs or vehicle administered 30 min before
the session. Animals in each group were allowed at least two days of
stable responding before they were retested with a different dose of
either AM630 or AM1241.
Testing AM1241 under the PR schedule of reinforce-
ment. A separate group of animals (N= 8) was trained to
self-administer 30 mg/kg/infusion nicotine under the FR1
schedule for 5 days, then the FR2 schedule for 3 days and the
FR5 schedule for another 2 days and then were directly switched
to a progressive-ratio (PR) schedule where the response require-
ment during the session increased with each successive injection.
The response requirement progression was based on the formula
5e(0.25 inj number)-5, with the first two values replaced by 5 and 10
CB2 Receptors and Reinforcing Effects of Nicotine
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requirements for successive injections were 5, 10, 17, 24, 32, 42,
56, 73, 95, 124, 161, 208, etc.. PR sessions lasted a maximum of
4 h. However, if the animal ceased to press the active lever for
30 minutes, the session automatically ended and the last ratio
completed by the animal was defined as the break point. The
animals were allowed 10 days of nicotine self-administration under
the PR schedule and testing was performed only after stabilization
of the responding on the active lever for at least 2 consecutive
sessions before testing with AM1241 compound began. All animals
reached their break points during the 4-h sessions within this 10-
day training period and testing of vehicle (0 mg/kg) and AM1241
(1,3 and 10 mg/kg, IP, 30 min before the session) was then
performed.
Testing AM630 under the PR schedule of reinforce-
ment. The same group of animals that were tested with
AM630 under the FR schedule of reinforcement ( N=12) were
switched to the PR schedule. After stabilization of behavior under
the PR schedule for 2 successive sessions, animals were tested using
vehicle (0 mg/kg) and the highest dose of AM630 (5 mg/kg) in a
counterbalanced, within-subject design, in a similar fashion to that
described with AM1241. Only 7 animals completed testing under
the PR schedule; 5 animals were excluded due to catheter blockade.
Extinction. After acquisition of nicotine self-administration
behavior, as described above, an extinction phase was conducted
by withholding nicotine and its associated cues (house light
remained on and cue lights remained off throughout the session).
Responses on the active and inactive lever were recorded, but had
no programmed consequences. An extinction criterion was
established for each animal individually and was defined as total
active lever responses during the session being less than 20 presses.
This extinction criterion had to be maintained for 2 consecutive
days before testing. All animals reached the extinction criterion
within an average of 12 extinction sessions.
Effects of AM1241 on cue induced reinstatement of
nicotine-seeking behavior. All tests were carried out in a
counter-balanced within-subject design. After each test, extinction was
re-established until extinction criteria were obtained for at least two
consecutive days. Animals (N=11) were pretreated 30 min before the
session with vehicle (0 mg/kg) and 1, 3 and 10 mg/kg AM1241 in a
counterbalanced order to measure the effects of AM1241 on cue-
induced reinstatement of nicotine-seeking behavior. Cue induced
reinstatement tests were conducted under conditions identical to that
of self-administration, except that responses on the active lever (under
a FR5 schedule) resulted in contingent presentation of the cues (light
above the active lever on and house-light off for 60 s) without nicotine
availability (no infusions). Responses on the inactive lever were
recorded but had no programmed consequences. The testing sessions
lasted for 60 minutes.
Effects of AM1241 on nicotine induced reinstatement of
nicotine seeking. A new group of animals (N=13) underwent a
similar acquisition and extinction training procedure, as described
above with cue-induced reinstatement. This group was tested for
effects of vehicle (0 mg/kg) and AM1241 (1, 3 and 10 mg/kg IP
30 min before the session) on nicotine-induced reinstatement.
Nicotine priming was performed as in [26,27] by administering
0.15 mg/kg nicotine SC,10 min before the start of the test session.
Effects of AM630 on cue-induced and nicotine-induced
reinstatement of nicotine-seeking behavior. Two separate
groups of animals were tested for effects of AM630 on reinstatement
ofnicotine-seeking behaviorinducedbycues(N=9)andbynicotine
priming (N=9). Animals were pretreated with vehicle (0 mg/kg)
and AM630 (1.25, 2.5 and 5 mg/kg) IP 30 minutes before the start
of the session. Cue-induced reinstatement tests were conducted
under conditions identical to that of self-administration, except that
responses on the active lever (on an FR5 schedule) resulted in
contingent presentation of the cues (light above the active lever on
and house-light off for 60 s) without nicotine availability (no
infusions).Responsesontheinactiveleverwererecordedbuthad no
programmed consequences. Testing the effects of AM630 on
nicotine-induced reinstatement was performed as in [26] by
administering 0.15 mg/kg nicotine SC, 10 min before the start of
test session, in the same manner and using the same methodology as
described above with AM1241. All extinction and reinstatement
sessions lasted for 60 minutes.
Data Analysis
The number of active and inactive lever presses and the number
of nicotine infusions were recorded and analyzed. To analyze the
effects of AM1241 and AM630 on the number of nicotine
infusions earned under the FR and the PR schedules of
reinforcement, one way ANOVA analysis was performed. For
reinstatement studies, one-way repeated measures analysis of
variance (ANOVA) was used to assess the effects of AM1241 and
AM630 on reinstatement induced by nicotine priming and by
nicotine-associated cues. Student-t test was used to assess the effect
of 5 mg/kg of AM630 pretreatment compared to vehicle
pretreatment on nicotine self-administration behavior under the
PR schedule of reinforcement.
Drugs
(-)Nicotine hydrogen tartrate (Sigma-Aldrich, St Louis, Mo., USA)
was dissolved in saline, the pH was adjusted to 7.0 (60.2), and the
solution was filtered through a 0.22 mm syringe filter (Fisher
Scientific, Pittsburgh, Pa., USA) for sterilization purposes. All nicotine
doses are reported as free base concentrations. Nicotine was
administered IV in a volume of 100 ml/kg/injection for self-
administration studies or was administered SC at the dose of
0.15 mg/kg for reinstatement studies. AM1241 (2-iodo-5-nitrophe-
nyl)-(1-(1-methylpiperdin-2-ylmethyl)-1 h-indol-3-yl) methanone was
dissolved in 20% DMSO in saline and injected IP 30 min before the
start of the session and was synthesized by the group of Dr.
Alexandros Makriyannis, the Centre for Drug discovery at
Northeastern University, Boston, MA, USA .AM630 (6-Iodo-2-
methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-
methanone) (Tocris Bioscience, Missouri USA) was dissolved in
10%DMSO, 10% tween in distilled water and injected IP in a
volume of 1 ml/kg 30 min before the start of the session.
Results
Acquisition of nicotine self-administration behavior
under fixed ratio schedule of reinforcement
During the first week of acquisition, responding on the active
lever decreased to low levels, then gradually increased when the
ratio requirement was increased up to FR5; in contrast,
responding on the inactive lever remained low (Fig. 1A). Over
the next 2 weeks, responding on the active lever under the FR5
schedule that was reinforced by nicotine infusion increased to the
high levels previously maintained by food, while responding on the
inactive lever remained low. The number of nicotine infusions
throughout the different schedules of reinforcement (FR1 – FR5)
showed a consistent level of nicotine self administration (above 10
infusions/session) (Fig. 1B).
Extinction
The data presented in Fig. 1C reflect the extinction pattern for
the group of animals (N=12) used in the experiment testing the
CB2 Receptors and Reinforcing Effects of Nicotine
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completed testing on cue-induced reinstatement and 1 animal was
excluded due to failure of extinction). Most animals reached
extinction criteria within 8–9 days and testing with AM1241 on
reinstatement was started (extinction training was pursued for the
remaining rats until they reached the extinction criteria).
Effects of AM1241 on nicotine self-administration
behavior under the FR5 schedule
ANOVA analysis showed no significant effect of AM1241
pretreatment on the number of nicotine infusions (F3, 27=1.13,
P=0.35), and pair wise comparisons with vehicle (0 mg/kg)
indicated that administration of AM1241 (1, 3 and 10 mg/kg) did
not affect the number of nicotine infusions received during the
session (N=10) (Fig. 2A).
Effects of AM1241 on nicotine self-administration
behavior under the PR schedule
ANOVA analysis showed no significant effect of AM1241
pretreatment on the number of nicotine infusions (F3, 21=0.20,
P=0.89). Administration of various doses of AM1241 (1, 3 and
10 mg/kg) failed to produce any change in break point values, as
compared to vehicle (0 mg/kg; N=8) (Fig. 2B).
Effect of AM1241 on reinstatement of nicotine-seeking
behavior induced by nicotine-associated cues
ANOVA analysisperformed onactive lever pressesindicateda main
effect of cues per se on reinstatement of nicotine seeking compared to
extinction (Ext) conditions (P,0.001). Newman-Keuls Multiple
Comparison Test performed on the active lever presses indicated no
effect of AM1241 administration (F4, 40=19.75; P.0.05), compared to
cue-induced reinstatement after vehicle (0 mg/kg) administration.
Neither presentation of nicotine-associated cues nor AM1241
administration, had a significant effect on responding on the inactive
lever (F4, 40=1.34, P=0.27) (N=11)(Fig. 3A).
Effect of AM1241 on reinstatement of nicotine-seeking
behavior induced by nicotine priming
ANOVA analysis performed on active lever presses indicated a
main effect of 0.15 mg/kg nicotine priming on nicotine-seeking
behavior, as compared to extinction (Ext) conditions (P,0.001).
ANOVA analysis performed on the active lever presses indicatedno
effect of AM1241 (F3, 36=6.64; P.0.05), as compared to nicotine-
induced reinstatement after vehicle (0 mg/kg) pretreatment.
Neither priming injections of nicotine, nor AM1241 (1, 3 and
10 mg/kg) administration, had a significant effect on responding on
the inactive lever (F3, 36=1.80; P=0.14) (N=13)(Fig. 3B).
Effects of AM630 on nicotine self-administration behavior
under the FR5 schedule
ANOVA showed no effect of AM630 pretreatment on the
number of nicotine infusions received during the session (F3, 33
=0.51, P=0.67), and pair wise comparisons with vehicle (0 mg/
kg) pretreatment indicated that administration of AM630 (1.25,
2.5 and 5 mg/kg) did not affect the number of nicotine infusions
received during the session (N=12) (Fig. 4A).
Effects of AM630 on nicotine self-administration behavior
under the PR schedule
Student-t test showed no effect of AM630 pretreatment on the
number of nicotine infusions received during the session (P=0.73).
Administration of 5 mg/kg AM630 failed to produce any change
Figure 1. Pattern of respondinng during acquisition and extinction phases. A. Acquisition of nicotine self-administration (30 mg/kg/
infusion). The total number of active (N) and inactive(&) lever presses (means 6 SEM) received in each session (during time in and time out periods)
under the different schedules of reinforcement (FR- 1, FR-2, FR-5,). B. Number of nicotine infusions (means 6 SEM) earned during acquisition phase in
the same group of animals represented as fig. 1A. C. The number of active (N) and inactive(&) lever presses (means 6 SEM) received in each extinction
session in the same group of animals represented in figures 1A & 1B.
doi:10.1371/journal.pone.0029900.g001
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(Fig. 4B)(N=7).
Effects of AM630 on reinstatement of nicotine-seeking
behavior induced by nicotine-associated cues
ANOVA analysis performed on active lever presses indicated a
main effect of cues per se on reinstatement of nicotine-seeking
behavior compared to extinction (Ext) conditions (P,0.001).
ANOVA performed on the active lever presses indicated no effect
on cue-induced reinstatement. of different doses of AM630 (1.25,
2.5 and 5 mg/kg) (F4, 32=14.94; P.0.05), compared to vehicle
(0 mg/kg). Neither presentation of nicotine-associated cues, nor
administration of AM630, had a significant effect on responding
on the inactive lever (F4, 32=0.50 P=0.73)( N=9) (Fig. 5A).
Effects of AM630 on reinstatement of nicotine-seeking
behavior induced by nicotine priming
ANOVA analysis performed on active lever presses indicated a
main effect of 0.15 mg/kg nicotine priming on nicotine-seeking
behavior, compared to extinction (Ext) conditions (P,0.001).
Figure 2. Effects of AM1241 on nicotine self-administration under FR5 and PR schedules of reinforcement. A. Effects of pretreatment
with AM1241 (1, 3 and 10 mg/kg, IP H 30) on nicotine (30 mg/kg/infusion) self-administration under the FR5 schedule. Data are expressed as means
(6SEM) of the number of nicotine infusions obtained during the 60-min session. All doses of AM1241 did not affect responding vs. vehicle (0 mg/kg)
pretreatment (N=10); P=0.35. B. Effects of pretreatment with AM1241 (1, 3 and 10 mg/kg) on nicotine (30 ug/kg/infusion) self- administration under
PR schedule. A, Data are expressed as means (6SEM) of the number of nicotine infusions obtained during the 4-hr sessions. AM1241 did not affect
break point P.0.05 compared to vehicle (0 mg/kg) pretreatment. (N=8) P=0.89.
doi:10.1371/journal.pone.0029900.g002
Figure 3. Effects of AM1241 on reinstatement of nicotine-seeking behavior induced by presentation of nicotine associated cues
and by Nicotine priming. A. A significant reinstatement of nicotine-seeking behavior was produced by presentation of nicotine associated cues
alone compared to extinction condition (Ext) (* P,0.001). ANOVA showed that pretreatment with AM1241 (1, 3 and 10 mg/kg, IP, H 30 min) did not
modify cue induced reinstatement of nicotine-seeking behavior compared to vehicle (0 mg/kg) (P.0.05) N=11. Data are expressed as means (6SEM)
of the number of active and inactive lever presses during extinction (Ext); vehicle (0 mg/kg) pre-treatment (visual cues) and after pretreatment with
AM121 (1, 3 and 10 mg). B. A significant reinstatement of nicotine-seeking was produced by pretreatment with nicotine (0.15 mg/kg) compared to
extinction condition (Ext) (* P,0.001). ANOVA showed that AM1241 (1, 3, 10 mg/kg, IP, H 30 min) did not modify reinstatement of nicotine-seeking
behavior induced by a priming injection of 0.15 mg/kg nicotine administered 1 min before the session compared to vehicle (0 mg/kg) pretreatment
(P.0.05). Data are expressed as means (6SEM) of the number of active and inactive lever presses during extinction (Ext); vehicle (0 mg/kg) pre-
treatment and after pretreatment with AM121 (1, 3 and 10 mg). N=13.
doi:10.1371/journal.pone.0029900.g003
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effects of administration of AM630 (1.25, 2.5 and 5 mg/kg) (F4, 32
=8.33; P.0.05), as compared to vehicle (0 mg/kg) pretreatment.
Neither priming injections of nicotine nor AM630 administration,
had a significant effect on responding on the inactive lever (F4,
32=0.73; P=0.57)(N=9) (Fig. 5B).
Discussion
This study is the first to evaluate the impact of selective CB2
receptor ligands on an animal model of nicotine-taking and
nicotine-seeking behavior. Neither activation of CB2 receptors by
the selective CB2 agonist AM1241, nor blockade using the
selective CB2 antagonist AM630 produced significant effects on
nicotine-taking behavior under fixed-ratio or progressive-ratio
schedules of reinforcement. Moreover, both compounds failed to
modulate nicotine-seeking behavior induced by reintroduction of
nicotine-associated cues or by priming injections of nicotine just
before the start of the session.
To our knowledge, data on the behavioral properties of
AM1241 are relatively scarce and are mostly limited to studying
its effects on motor function and pain. We selected a dose range
that covers the different doses used in several previous studies
[28–30], doses that had potent antinociceptive effects, but, no
locomotor, cataleptic or motor side effects [31,32]. Similarly,
AM630 has seldom been tested in drug dependence paradigms.
Similar to AM1241, we used a relatively wide range of AM630
doses similar to doses previously tested [33,34]. Choice of AM630
was due to its high potency and affinity for rat CB2 receptors
[35].
Our results with AM1241 on nicotine self administration under
the fixed-ratio schedule of reinforcement are in agreement with
previous results with the CB2 agonist JWH015, which failed to
modulate alcohol intake in C57Bl/6 mice under a fixed-ratio
schedule of reinforcement [13]. Furthermore, selective blockade of
CB2 receptors by AM630 did not affect alcohol intake in the same
strain of mice under the same schedule of reinforcement [13].
However, both JWH015 and AM630 were able to increase and
decrease alcohol intake, respectively, in mice subjected to chronic
mild stress, which is a paradigm outside the scope of this study
[13]. These findings were later replicated by the same group which
also reported that blockade of CB2 receptors decreased food
consumption in C57Bl/6 mice but failed to produce significant
changes in food intake for Balb/c and DBA/2 mice [36].
In contrast to our findings, Xi et al. have recently shown that
systemic, intranasal and local intra-accumbens administration of
the selective CB2 agonist JWH133, produced a dose dependent
decrease in intravenous cocaine self-administration behavior, in
cocaine-induced hyperlocomotion, and in cocaine-induced in-
creases in extracellular levels of dopamine in the nucleus
accumbens in wild-type and CB1 receptor knockout mice, but
not in CB2 knockout mice [15]. The effects observed with CB2
receptor activation were reversed by the selective CB2 antagonist
AM630 [15]. The difference between our findings and the findings
by Xi and colleagues may be due to differences in the
neurobiological substrates of the drug of abuse studied (nicotine
vs. cocaine), differences in the role of CB2 receptors based on the
animal strain (rats vs. mice), differences in the pharmacological
effects of the CB2 agonist used (JWH133 vs. AM1241, or
differences in the schedule of reinforcement used (FR5 vs. FR1).
Further work addressing those factors would be needed to clarify
the role of CB2 receptors in drug reinforcement.
The behavioral findings in this study are in apparent contrast
with our recent findings that stimulation of CB1/2 receptors using
the mixed CB1/2 receptor agonist WIN 55,212-2 increases
nicotine self-administration behavior under a progressive-ratio
schedule of reinforcement.
Moreover, in the same study, we demonstrated that adminis-
tration of WIN 55,212-2 per se reinstates nicotine-seeking
behavior, an effect that was reversed by the selective CB1 inverse
agonist/antagonist rimonabant but not by the selective CB2
antagonist AM630, indicating that this enhancement of nicotine-
seeking behavior was mediated by CB1 receptors. WIN 55,212
also significantly enhanced reinstatement of nicotine-seeking
behavior induced by reintroduction nicotine associated cues, an
effect that was also reversed by rimonabant [21].
The results in this study, along with our previous work on CB1
receptor stimulation, add more evidence to the current literature
that CB1 and CB2 receptors have several distinct behavioral,
neurochemical and immunological profiles, yet they overlap in
some properties like antinociception, catalepsy (when higher doses
are tested) [30,37].
Figure 4. Effect of AM630 on nicotine self administration under FR5 and PR schedules of reinforcement. A. Effects of pretreatment with
AM630 (1.25, 2.5 and 5 mg/kg, IP, H 30) on nicotine (30 mg/kg/infusion) self administration under the FR5 schedule. Data are expressed as means
(6SEM) of the number of nicotine infusions obtained during the 60-min session. AM630 did not affect responding vs. vehicle (0 mg/kg) pretreatment
(N=12); P=0.67. B. Effects of pretreatment with AM630 (5 mg/kg, IP) on nicotine (30 ug/kg/infusion) self administration under PR schedule. A, Data
are expressed as means (6SEM) of the number of nicotine infusions obtained during the 4-hr sessions. AM630 did not affect break point P.0.05 vs.
vehicle (0 mg/kg) pretreatment. (N=7) P=0.73.
doi:10.1371/journal.pone.0029900.g004
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reinstatement. This aspect would be worth exploring in further
studies. It is clear that neurotransmitters, such as noradrenaline
and corticotrphin releasing factor, are involved in mediating stress-
induced reinstatement [38] and we cannot exclude an involvement
of CB2 receptors in stress-induced reinstatement of nicotine-
seeking behavior at this point.
In conclusion, the findings in this study provide evidence that
CB2 receptors are not involved in the reinforcing effects of
nicotine and in reinstatement of nicotine-seeking behavior induced
by cues and nicotine priming in rats. In this study we used the
intravenous mediated paradigm which has been previously used
by us and several other laboratories to assess the pivotal role CB1
receptors play in the reinforcing effects of nicotine, yet in this study
using the same paradigm we were not able to demonstrate a
similar role of CB2 receptors on nicotine self-administration
behavior or reinstatement of nicotine seeking behavior. Hence, we
believe that ligands modulating the CB1 receptors (either directly
or indirectly by modulating endocannabinoid tone) could
potentially be a more useful tool than CB2 ligands in modulating
the reinforcing and relapse related effects of nicotine [23,39–41].
The findings in this study could be specific to nicotine and not
generalizable to other drugs of abuse. Therefore, further studies
are warranted to investigate the role of CB2 receptors on the
reinforcing and relapse related effects different drugs of abuse.
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